Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Seliciclib - Cyclacel Pharmaceuticals

Next Previous
X
Search
Drug Profile

Seliciclib - Cyclacel Pharmaceuticals

Alternative Names: CYC 202; R-roscovitine; Seliciclib

Latest Information Update: 06 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cyclacel Pharmaceuticals
  • Developer Cedars-Sinai Health System; Cyclacel Pharmaceuticals; University Hospital, Brest; University of Newcastle upon Tyne
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cell cycle protein inhibitors; Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase 9 inhibitors; Cyclin-dependent kinase-activating kinase inhibitors; MCL1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis; Nasopharyngeal cancer; Non-small cell lung cancer; Pituitary ACTH hypersecretion; Rheumatoid arthritis
  • No development reported Breast cancer; Cushing syndrome
  • Discontinued Glomerulonephritis; Haematological malignancies; Solid tumours

Most Recent Events

  • 06 Jan 2023 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease) in USA (PO)
  • 02 Jan 2023 No development reported - Phase-II for Cushing syndrome in USA (PO)
  • 28 Dec 2020 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in USA (PO, Capsule)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top